Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung Adenocarcinoma

Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung... RESEARCH ARTICLE Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung Adenocarcinoma Alexander J.J. Smits, MD,*w Aryan Vink, MD, PhD,w Gerda Tolenaars, BSc,* Gerarda J.M. Herder, MD, PhD,z and Jean Alain Kummer, MD, PhD* (Appl Immunohistochem Mol Morphol 2015;23:416–421) Abstract: With the use of more specific treatments and targeted therapies for non–small cell lung carcinoma, distinction between adenocarcinoma (ADC) or squamous cell carcinoma (SCC) hyroid transcription factor-1 (TTF-1) is a homeo- becomes increasingly important. For this, the key technique is Tdomain transcription factor that is expressed in epi- an immunohistochemical panel in which a thyroid transcription thelial cells of the thyroid, diencephalon, Clara cells, type factor-1 (TTF-1) antibody is often used. Two different TTF-1 II pneumocytes, and basal bronchiolar epithelial cells of clones (8G7G3/1 and SPT24) are used in daily practice, which the lung. It is also expressed in thyroid adenocarcinomas appear to have different sensitivities and specificities. The aim of (ADCs), the majority of ADCs of the lung, and most this study was to assess the differences between these clones and small cell lung carcinomas. In contrast, squamous cell to identify the optimal cutoff value for correctly diagnosing 1,2 carcinomas (SCCs) of the lung http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung Adenocarcinoma

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/different-cutoff-values-for-thyroid-transcription-factor-1-antibodies-33owfG1o9L

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000099
pmid
25356948
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung Adenocarcinoma Alexander J.J. Smits, MD,*w Aryan Vink, MD, PhD,w Gerda Tolenaars, BSc,* Gerarda J.M. Herder, MD, PhD,z and Jean Alain Kummer, MD, PhD* (Appl Immunohistochem Mol Morphol 2015;23:416–421) Abstract: With the use of more specific treatments and targeted therapies for non–small cell lung carcinoma, distinction between adenocarcinoma (ADC) or squamous cell carcinoma (SCC) hyroid transcription factor-1 (TTF-1) is a homeo- becomes increasingly important. For this, the key technique is Tdomain transcription factor that is expressed in epi- an immunohistochemical panel in which a thyroid transcription thelial cells of the thyroid, diencephalon, Clara cells, type factor-1 (TTF-1) antibody is often used. Two different TTF-1 II pneumocytes, and basal bronchiolar epithelial cells of clones (8G7G3/1 and SPT24) are used in daily practice, which the lung. It is also expressed in thyroid adenocarcinomas appear to have different sensitivities and specificities. The aim of (ADCs), the majority of ADCs of the lung, and most this study was to assess the differences between these clones and small cell lung carcinomas. In contrast, squamous cell to identify the optimal cutoff value for correctly diagnosing 1,2 carcinomas (SCCs) of the lung

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Jul 1, 2015

There are no references for this article.